1. Market Research
  2. > Osteopenia - Pipeline Review, H1 2013

Osteopenia - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 29 pages

Osteopenia - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Osteopenia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteopenia. Osteopenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Osteopenia.
- A review of the Osteopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteopenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Osteopenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteopenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Osteopenia - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Osteopenia Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Osteopenia 6
Osteopenia Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Osteopenia Therapeutics - Products under Development by Companies 11
Companies Involved in Osteopenia Therapeutics Development 12
Amgen Inc. 12
Novartis AG 13
Pfizer Inc. 14
Osteopenia - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
AMG-167 - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
RN-564 - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
BPS-804 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Pro-Bone - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Osteopenia Therapeutics - Discontinued Products 24
Osteopenia Therapeutics - Dormant Products 25
Osteopenia - Product Development Milestones 26
Featured News and Press Releases 26
Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-111 In Patients With Tibial Plateau Fractures 26
Sep 19, 2007: Increased Bone Mineral Density Seen In Phase IIB Study With Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor. 26
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables


Number of Products Under Development for Osteopenia, H1 2013 6
Products under Development for Osteopenia - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Mid Clinical Stage Development, H1 2013 9
Comparative Analysis by Early Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Amgen Inc., H1 2013 12
Novartis AG, H1 2013 13
Pfizer Inc., H1 2013 14
Assessment by Monotherapy Products, H1 2013 15
Assessment by Stage and Route of Administration, H1 2013 17
Assessment by Stage and Molecule Type, H1 2013 19
Osteopenia Therapeutics - Discontinued Products 24
Osteopenia Therapeutics - Dormant Products 25

List of Figures


Number of Products under Development for Osteopenia, H1 2013 6
Products under Development for Osteopenia - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Mid Clinical Stage Products, H1 2013 9
Early Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 15
Assessment by Route of Administration, H1 2013 16
Assessment by Stage and Route of Administration, H1 2013 17
Assessment by Molecule Type, H1 2013 18
Assessment by Stage and Molecule Type, H1 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.